Eris Lifesciences has informed the stock exchanges about the completion of Mr. Rajeev Dalal's tenure as Non-Executive Independent Director, which will conclude on December 18, 2025. The announcement was made through a regulatory filing under Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015.

Director Tenure Details

Mr. Rajeev Dalal (DIN: 00222650) was appointed as a Non-Executive Independent Director for a term of five consecutive years. His appointment was approved by the company's members at their Fifteenth Annual General Meeting held on September 1, 2021, with the tenure commencing from December 19, 2020.

Impact on Board Committees

Consequent upon the completion of Mr. Dalal's term as Non-Executive Independent Director, his membership and chairmanship in various committees of the Board will also cease to exist with effect from the close of business hours on December 18, 2025.

Company's Acknowledgment

The Board of Directors and Management of Eris Lifesciences have extended their sincere appreciation for the valuable contributions made by Mr. Rajeev Dalal during his five-year tenure as an Independent Director. The company has formally communicated this development to both BSE Limited and the National Stock Exchange of India Limited as part of its regulatory compliance obligations.

The filing was signed by Milind Talegaonkar, Company Secretary and Compliance Officer (Membership No: A26493), ensuring proper adherence to the disclosure requirements under the SEBI regulations.

Eris Lifesciences Limited has informed stock exchanges about an upcoming virtual investor meeting scheduled for December 18, 2025, as per the requirements of Regulation 30 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015.

Meeting Details

The pharmaceutical company has provided comprehensive details about the scheduled investor interaction:

Institutional Participants

The investor meeting will see participation from several prominent institutional investors and asset management companies. The confirmed participants include:

• Axis Mutual Fund
• ICICI Prudential Asset Management
• Universal Sompo General Insurance Company Limited

Regulatory Compliance and Disclosure

The company has emphasized its commitment to regulatory compliance and transparency in its communication to BSE Limited and National Stock Exchange of India Limited. Eris Lifesciences has clarified that the meeting schedule is indicative and subject to changes due to any unforeseen developments.

Importantly, the company has stated that discussions during the investor interaction will be based solely on publicly available documents. The management has explicitly confirmed that no unpublished price-sensitive information (UPSI) is intended to be discussed during the meeting, ensuring compliance with insider trading regulations.

Company Information

The notification was signed by Milind Talegaonkar, Company Secretary and Compliance Officer (Membership No: A26493), and submitted to both major stock exchanges where the company is listed. Eris Lifesciences trades on BSE with security code 540596 and on NSE with the symbol ERIS.

The company maintains its registered corporate office at Shivarth Ambit, Plot No. 142/2, Ramdas Road, Off SBR, Near Swati Bungalows, Bodakdev, Ahmedabad-380054, and operates under CIN: L24232GJ2007PLC049867.